THE ANALYSIS "MINIMIZATION OF EXPENSES" OF USE НООТРОПНЫХ OF PREPARATIONS IN TREATMENT OF PATIENTS WITH THE STROKE
The method of minimizing costs was conducted pharmacoeconomic analysis of neuroprotective drugs included in the standard of care for patients with stroke, as well as neuroprotective drugs chastonaznaemyh: etilmetilgidroksipiridina succinate (meksidol)methionyl-glutamyl-histidyl-phenylalanyl-prolyl-gly-cyl-proline (Semax), vinpocetine (cavinton), glycine, Actovegin, Cortexin, piracetam, citicoline (tserakson), Cerebrolysin, choline alfostserat (Gliatilin, Cerepro, tsereton) and combined prepatat Piracetam + cinnarizine (fezam). It is shown that most patients received drugs - actovegin (42. 14% of patients), piracetam (47. 16%) cavinton (26. 41%), glycine (21. 38%) and meksidol (19. 49%).With respect to the use of similar effectiveness Cavinton and piracetam in stroke associated with lower direct medical costs compared with the rest appointed by the nootropic agents and pharmacoeconomic is most appropriate.